Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AlzeCure Pharma
Adjusted Timeline for the Previously Communicated Rights Issue
May 27, 2026
Last Patient has Completed AlzeCure’s Phase Ib Clinical Study with NeuroRestore ACD856
May 25, 2026
AlzeCure Pharma Publishes its Annual Report for 2025
May 23, 2026
AlzeCure Pharma to Present at Redeye Healthcare Day on April 14
May 23, 2026
AlzeCure Pharma to Present at Redeye Alzheimer’s Theme Event on April 9
May 23, 2026
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD
May 20, 2026
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11
May 16, 2026
AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million
April 30, 2026
AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer’s conference AP/PD 2026
February 3, 2026
AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam
February 2, 2026